Coronary Arteriosclerosis, Coronary Artery Disease, Diabetes Mellitus, Type 2
Conditions
Brief summary
To assess the relationship between serum endostatin (ES) and Coronary artery calcification (CAC) in type 2 diabetic (T2DM) patients.
Detailed description
elevated serum endostatin levels were independently associated with increased risk, severity and progression of coronary artery calcification independent of traditional cardiovascular disease risk factors in T2DM subjects with known coronary artery disease. So, Measurement of serum ES levels can improve the diagnosis of coronary artery calcification and could be useful as a high sensitive marker for the presence and progression of atherosclerosis in T2DM patients.
Interventions
DIAGNOSTIC_TESTserum endostatin level
An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding. Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R&D Systems, Minneapolis, Minnesota, USA
Sponsors
Zagazig University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
- Patients were between the ages of 50 and 70 years at enrollment. * Symptomatic or previously recognized coronary artery disease for all the study population. * Type 2 diabetic patients with the onset of type 2 diabetes occurred at age 30 years or older with no history of ketoacidosis for group II subjects.
Exclusion criteria
* left ventricular ejection fraction (LVEF) ≤40%, chronic heart failure, unstable angina, Myocardial infarction, arrhythmia, valvular heart disease, coronary artery bypass surgery, and history of stent placement, liver diseases, malignancy, glomerular filtration rate index \< 35 mL/min/m2, serum creatinine level above 4.5 mg/dL, body mass index \>30 kg/m2 or \< 15 kg/m2, pulmonary edema, stroke, acute infections, severe trauma, recent surgery, inflammatory conditions, thyrotoxicosis, pregnancy and known allergic reactions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients with Coronary Heart Disease | 3-Months | Measurement of serum endostatin and Coronary artery calcification in type 2 diabetic patients patients and non-diabetic patients. |
Countries
Egypt
Outcome results
None listed